NZ622260A - Toll-like receptor 3 antagonists - Google Patents

Toll-like receptor 3 antagonists

Info

Publication number
NZ622260A
NZ622260A NZ622260A NZ62226011A NZ622260A NZ 622260 A NZ622260 A NZ 622260A NZ 622260 A NZ622260 A NZ 622260A NZ 62226011 A NZ62226011 A NZ 62226011A NZ 622260 A NZ622260 A NZ 622260A
Authority
NZ
New Zealand
Prior art keywords
toll
receptor
antagonists
cholesterol
ldl
Prior art date
Application number
NZ622260A
Inventor
Mark Cunningham
Yiqing Feng
Katharine Heeringa
Jinquan Luo
Robert Rauchenberger
Mark Rutz
Mateo Lani San
Robert Sarisky
Vedrana Stojanovic-Susulic
Raymond Sweet
Fang Teng
Alexey Teplyakov
Linda Wu
Sheng-Jiun Wu
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of NZ622260A publication Critical patent/NZ622260A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a method of lowering levels of fat accumulation, low density lipoprotein (LDL), or cholesterol; or treating cardiovascular disease by lowering LDL/cholesterol, comprising administering a therapeutically effective amount of an isolated antibody reactive with TLR3 (Toll-Like Receptor 3)
NZ622260A 2011-09-12 2011-09-12 Toll-like receptor 3 antagonists NZ622260A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/051202 WO2013039471A1 (en) 2011-09-12 2011-09-12 Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases

Publications (1)

Publication Number Publication Date
NZ622260A true NZ622260A (en) 2016-11-25

Family

ID=47883555

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ622260A NZ622260A (en) 2011-09-12 2011-09-12 Toll-like receptor 3 antagonists

Country Status (11)

Country Link
EP (1) EP2755685A4 (en)
JP (1) JP2014526464A (en)
KR (1) KR20140075708A (en)
CN (1) CN104159610A (en)
BR (1) BR112014005786A2 (en)
CA (1) CA2855955A1 (en)
EA (1) EA201490623A1 (en)
IL (1) IL231413A0 (en)
MX (1) MX362457B (en)
NZ (1) NZ622260A (en)
WO (1) WO2013039471A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6366195B2 (en) * 2013-04-22 2018-08-01 国立大学法人 東京大学 Preventive or therapeutic agent for inflammatory diseases
WO2015016282A1 (en) * 2013-07-30 2015-02-05 国立大学法人東京大学 Pharmaceutical composition for preventing or treating radiation-induced gastrointestinal syndrome
CA2985718A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
PE20231655A1 (en) 2015-10-02 2023-10-17 Hoffmann La Roche BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
CN101415438B (en) * 2004-11-30 2013-03-27 森托科尔公司 TOLL like receptor 3 antagonists, methods and uses
AR051836A1 (en) 2004-11-30 2007-02-14 Centocor Inc RECEIVER ANTAGONISTS 3 SIMIL TOLL METHODS AND USES
JP2010527633A (en) * 2007-05-25 2010-08-19 セントコア・オーソ・バイオテツク・インコーポレーテツド Toll-like receptor 3 modulator and use thereof
US8895263B2 (en) * 2008-10-02 2014-11-25 Janssen Biotech, Inc. Methods for suppressing toll-like receptor activity
WO2010045340A1 (en) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
LT2350304T (en) * 2008-10-31 2017-02-10 Janssen Biotech, Inc. Toll-like receptor 3 antagonists
SI2425008T1 (en) * 2009-04-29 2015-12-31 Janssen Biotech, Inc. Toll-like receptor 3 antagonists

Also Published As

Publication number Publication date
BR112014005786A2 (en) 2017-03-28
IL231413A0 (en) 2014-04-30
CN104159610A (en) 2014-11-19
WO2013039471A1 (en) 2013-03-21
JP2014526464A (en) 2014-10-06
EP2755685A1 (en) 2014-07-23
KR20140075708A (en) 2014-06-19
MX362457B (en) 2019-01-18
EP2755685A4 (en) 2015-07-01
EA201490623A1 (en) 2016-01-29
CA2855955A1 (en) 2013-03-21
MX2014002982A (en) 2015-07-06

Similar Documents

Publication Publication Date Title
IL284530A (en) Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
IL281178B (en) Methods of treating or preventing cholesterol related disorders
NZ622260A (en) Toll-like receptor 3 antagonists
GB2503623B (en) A method for predicting a result of a treatment of keratinous fibers
MX2019011905A (en) New compositions for treating amyotrophic lateral sclerosis.
WO2013101451A8 (en) Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
GB201214731D0 (en) Golf coupling mechanisms and related methods
IN2014CN03073A (en)
MX2013012526A (en) Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders.
GB201214733D0 (en) Golf coupling mechanisms and related methods
EP3162931C0 (en) Method for the manufacture of fibrous yarn
PL2564822T3 (en) Method for producing a sheet of material from which elastically extendable nappy closers can be stamped
PL2688948T3 (en) Process for the preparation of an accelerator solution
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
IL232190A0 (en) Methods of treating inflammatory disorders using anti-m-csf antibodies
BR112014000634A2 (en) Methods for treating incontinence associated with sexual activity
IN2014DN00254A (en)
EP2663323A4 (en) Methods targeting mir-128 for regulating cholesterol/lipid metabolism
MX343701B (en) Process for alkynylating 16-substituted-17-keto steroids.
MX355816B (en) Method for treating bone gap defects.
MX359697B (en) Method for treating schizophrenia.
EP2575883A4 (en) Treatment of inflammatory disorders
PL2488690T3 (en) Method for improving felting properties of animal fibres by plasma treatment
UA69974U (en) Method for correction of immune status of patients with nonalcoholic steatohepatitis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 SEP 2018 BY AJ PARK

Effective date: 20170620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2019 BY CPA GLOBAL

Effective date: 20180823

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2020 BY CPA GLOBAL

Effective date: 20190801

LAPS Patent lapsed